Zimmer Biomet Holdings ((ZBH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zimmer Biomet Holdings is conducting a Post-Market Clinical Follow-Up (PMCF) study titled ‘Post-Market Clinical Follow-Up Study to Provide Safety, Performance and Clinical Benefits Data of the RingLoc Bipolar Acetabular Cup or Endo II Heads (Implants and Instrumentation) in Hip Hemiarthroplasty.’ The study aims to gather data on the safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads used in hip hemiarthroplasty, addressing conditions such as hip arthritis and fractures.
The study is testing two medical devices: the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head. These devices are designed to improve hip function in patients undergoing hemiarthroplasty, a surgical procedure to address hip malfunctions or injuries.
This observational study follows a cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on collecting observational data from patients who have already received the devices.
The study was first submitted on January 5, 2022, and is not yet recruiting as of the last update on June 16, 2025. The timeline indicates that the study is in its early stages, with primary completion and estimated completion dates yet to be announced.
The outcome of this study could significantly impact Zimmer Biomet’s market position by reinforcing the safety and efficacy of its hip replacement products. Positive results may boost investor confidence and influence stock performance, especially in comparison to competitors in the orthopedic device industry.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.